It is widely accepted that, in addition to high PD‐L1 expression, tumor mutational burden and mismatch‐repair deficiency, as well as lymphocytes and other inflammatory cells also have a predictive role in immunotherapy response.11 Here, CD274 is linked to neoplasm.